2 April 2020 - - US-based medical screening device distributor PreCheck Health Services, Inc. (OTC: HLTY) has entered into a new exclusive distribution agreement with Co-Diagnostics Inc, the company said.

This agreement gives the company the exclusive distribution rights to Co-Diagnostics' qPCR infectious disease kits, Logix Smart COVID-19 PCR diagnostic test and Co-Dx Box instrument, in Afghanistan, Kazakhstan, Kyrgyzstan, Tajikistan, Turkmenistan and Uzbekistan.

This agreement follows the execution of agreements with Co-Diagnostics for Russia, Ecuador, Panama, Romania and Moldova. PreCheck's eleven combined distribution territories have an aggregate population of 298m.

PreCheck believes Co-Diagnostics' Coronavirus COVID-19 PCR test is the most accurate test to detect the presence of the COVID-19 infection. Co-Diagnostics has announced that it was the first US company to obtain a CE marking for a COVID-19 test.

CE marking is a certification mark that indicates conformity with health, safety, and environmental protection standards for products sold within the European Economic Area.

The CE marking is also found on products sold outside the EEA that have been manufactured to EEA standards.

PreCheck Health Services, Inc. is a distributor of the PC8B, a medical screening device, for use by physicians in managing a patient's health which it purchases from a domestic supplier, and, since March 2020, a distributor of Co-Diagnostics' tests, including its tests for the COVID-19.